MedGenome makes a majority investment in Siddhi Diagnostics & Research Centre  

IMT News Desk
IMT News Desk
· 2 min read
MedGenome makes a majority investment in Siddhi Diagnostics & Research Centre

MedGenome has joined hands with Siddhi Diagnostics & Research Centre (SDRC), a well-established diagnostic imaging service provider with a strong presence across Mumbai’s extended western suburbs.

Founded in 1995, SDRC is led by Dr. Ajit Pungavkar and Dr. Sona Pungavkar. Dr. Ajit, a renowned sonologist with over 35 years of clinical experience, has devoted his time and expertise to advancing the imaging-led diagnostic services in this region. Dr. Sona Pungavkar is a nationally recognized radiologist with about 30 years of clinical experience. A frequent speaker at both national and international conferences, she has published over 40 prestigious journal articles and received multiple awards in recognition of her contributions to the field. 

Surajit Chakrabartty, CFO of MedGenome, said, “By bringing together MedGenome’s strengths in genomics with SDRC’s established imaging capabilities, we can move closer to delivering a more complete view of a disease, combining structural and molecular insights to support earlier and more precise clinical decisions.”

SDRC caters to a large and diverse patient base through a mix of walk-in services, home collections, and partnerships with hospitals and laboratories, all under one roof. Its strong reporting and analytical expertise have helped build long-standing clinical trust, particularly in regions beyond Greater Mumbai, where access to high-quality diagnostic infrastructure has traditionally been limited.

Dr Ajit Pungavkar, Founder, SDRC, said, “In clinical practice, we often see cases where imaging alone does not provide the full picture, especially in complex or early-stage conditions. Through this partnership with MedGenome, we are now able to complement imaging findings with deeper molecular insights, which can significantly improve how clinicians interpret and act on diagnostic information. This brings a meaningful shift in how diagnostics are used, not just in identifying disease, but in guiding more precise and timely treatment decisions.”

Dr Sona Pungavkar, Co-founder and Medical Director, SDRC, said, “As diagnostics continues to evolve, the ability to integrate different layers of information becomes increasingly important. With the advancements in AI, today we are able to analyse the results of every evaluation holistically. Over time, this approach will help make advanced diagnostics more seamlessly integrated into routine care, improving both accessibility and the overall quality of clinical decision-making.”

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk